KLTO (Klotho Neurosciences) Ending Cash Position: $7.35 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLTO Klotho Neurosciences Inc KLTO
22 GF Score
Price $0.52
! 1 Warning Sign
View Full Analysis

What is Klotho Neurosciences Ending Cash Position?

Klotho Neurosciences KLTO 22 Ending Cash Position is $7.35 Mil as of Sep. 2025. GuruFocus rates KLTO with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Klotho Neurosciences's Ending Cash Position for the quarter that ended in Sep. 2025 was $7.35 Mil.

Klotho Neurosciences's quarterly Ending Cash Position increased from Mar. 2025 ($0.57 Mil) to Jun. 2025 ($8.43 Mil) but then declined from Jun. 2025 ($8.43 Mil) to Sep. 2025 ($7.35 Mil).

Klotho Neurosciences's annual Ending Cash Position declined from Dec. 2022 ($0.08 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.06 Mil).

Klotho Neurosciences Ending Cash Position Related Terms

Klotho Neurosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Klotho Neurosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klotho Neurosciences Ending Cash Position Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Ending Cash Position
0.30 0.08 0.00 0.06

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.57 8.43 7.35
KLTO
22GF Score
Klotho Neurosciences Inc KLTO
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klotho Neurosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Klotho Neurosciences's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.0030000000000001+0.061
=0.06

Klotho Neurosciences's Ending Cash Position for the quarter that ended in Sep. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.431+-1.083
=7.35

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $7.35 Mil mean?
Klotho Neurosciences (KLTO) has a Ending Cash Position of $7.35 Mil as of Sep. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' Ending Cash Position too high?
Klotho Neurosciences' current Ending Cash Position is $7.35 Mil. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' Ending Cash Position compare to KTTA and JUNS?
Klotho Neurosciences' Ending Cash Position of $7.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Klotho Neurosciences and its competitors. Klotho Neurosciences's current Ending Cash Position is $7.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current Ending Cash Position of $7.35 Mil. The current Ending Cash Position is $7.35 Mil. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current Ending Cash Position is $7.35 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Klotho Neurosciences Business Description

Address 13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score

Get the complete analysis for KLTO

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price